December 14, 2017 – Scenic appoints Chas Bountra to it’s scientific advisory board
Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, appoints Chas Bountra to its scientific advisory board.
Chas is Chief Scientist of the Structural Genomics Consortium, Professor at the Univ. of Oxford and Imperial College London. He is the former VP and Head of Biology at GSK. At GSK he was involved in the development of over 40 clinical candidates and the launch of alosetron. Dr Bountra is on the SAB of Carrick Tx, Spinifex Pharma, Axol Bioscience, Tekcapital and IP Asset Ventures. Chas is a world leader in drug discovery and development.